Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 10 | 2021 | 66 | 2.730 |
Why?
|
| Cytomegalovirus | 10 | 2020 | 91 | 1.730 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2020 | 674 | 1.220 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2021 | 6 | 0.730 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2020 | 181 | 0.720 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 65 | 0.660 |
Why?
|
| Immediate-Early Proteins | 2 | 2007 | 45 | 0.480 |
Why?
|
| Viral Matrix Proteins | 2 | 2007 | 50 | 0.480 |
Why?
|
| Infant | 8 | 2021 | 1650 | 0.460 |
Why?
|
| Phosphoproteins | 2 | 2007 | 220 | 0.440 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2015 | 641 | 0.440 |
Why?
|
| Viral Proteins | 2 | 2007 | 262 | 0.420 |
Why?
|
| Infant, Newborn | 6 | 2020 | 1356 | 0.310 |
Why?
|
| Evolution, Molecular | 3 | 2024 | 322 | 0.300 |
Why?
|
| Genetic Variation | 3 | 2015 | 383 | 0.270 |
Why?
|
| Biological Specimen Banks | 1 | 2024 | 23 | 0.220 |
Why?
|
| Specimen Handling | 1 | 2024 | 62 | 0.220 |
Why?
|
| Genetic Drift | 1 | 2024 | 16 | 0.220 |
Why?
|
| Herpesvirus 6, Human | 2 | 2014 | 17 | 0.210 |
Why?
|
| Humans | 24 | 2024 | 63299 | 0.200 |
Why?
|
| Monitoring, Immunologic | 1 | 2021 | 3 | 0.180 |
Why?
|
| Viral Load | 4 | 2022 | 231 | 0.180 |
Why?
|
| Tay-Sachs Disease | 1 | 2022 | 46 | 0.180 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 50 | 0.180 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 175 | 0.170 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2020 | 76 | 0.170 |
Why?
|
| Immune Evasion | 1 | 2020 | 68 | 0.160 |
Why?
|
| Sensitivity and Specificity | 4 | 2023 | 1146 | 0.160 |
Why?
|
| Immunocompromised Host | 2 | 2017 | 107 | 0.160 |
Why?
|
| Peptides | 2 | 2020 | 574 | 0.150 |
Why?
|
| Liver Transplantation | 1 | 2020 | 216 | 0.140 |
Why?
|
| Antigens, Viral | 4 | 2021 | 135 | 0.140 |
Why?
|
| Mycobacterium haemophilum | 1 | 2017 | 5 | 0.140 |
Why?
|
| Mycobacterium Infections | 1 | 2017 | 16 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 30 | 0.140 |
Why?
|
| Roseolovirus Infections | 2 | 2014 | 10 | 0.140 |
Why?
|
| Mothers | 1 | 2020 | 275 | 0.140 |
Why?
|
| DNA, Viral | 2 | 2015 | 232 | 0.130 |
Why?
|
| Genome, Viral | 2 | 2015 | 136 | 0.130 |
Why?
|
| DNA | 1 | 2021 | 832 | 0.130 |
Why?
|
| Crohn Disease | 1 | 2017 | 111 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2023 | 3283 | 0.120 |
Why?
|
| Information Seeking Behavior | 1 | 2014 | 38 | 0.110 |
Why?
|
| Cytomegalovirus Vaccines | 1 | 2013 | 5 | 0.100 |
Why?
|
| Pregnancy | 1 | 2020 | 2333 | 0.100 |
Why?
|
| Selection, Genetic | 1 | 2013 | 83 | 0.100 |
Why?
|
| Vaccines, DNA | 1 | 2013 | 98 | 0.100 |
Why?
|
| Interferon-gamma | 4 | 2013 | 566 | 0.100 |
Why?
|
| Saliva | 2 | 2024 | 103 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2014 | 255 | 0.090 |
Why?
|
| Female | 7 | 2024 | 32793 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2013 | 1007 | 0.090 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2011 | 30 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 262 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2012 | 242 | 0.080 |
Why?
|
| Peptide Mapping | 1 | 2007 | 29 | 0.070 |
Why?
|
| Data Collection | 2 | 2022 | 383 | 0.070 |
Why?
|
| Cell Line | 2 | 2012 | 2036 | 0.070 |
Why?
|
| Cell Line, Transformed | 2 | 2004 | 99 | 0.070 |
Why?
|
| Adult | 3 | 2024 | 16788 | 0.060 |
Why?
|
| United States | 3 | 2024 | 7829 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2014 | 2569 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 451 | 0.060 |
Why?
|
| Alleles | 1 | 2007 | 447 | 0.060 |
Why?
|
| Point-of-Care Testing | 1 | 2024 | 43 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1255 | 0.060 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2004 | 30 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2024 | 118 | 0.050 |
Why?
|
| HLA-A2 Antigen | 1 | 2004 | 64 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1592 | 0.050 |
Why?
|
| Nose | 1 | 2024 | 31 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2004 | 195 | 0.050 |
Why?
|
| Neoplasms | 1 | 2014 | 1361 | 0.050 |
Why?
|
| Young Adult | 2 | 2024 | 4686 | 0.050 |
Why?
|
| Middle Aged | 4 | 2024 | 17553 | 0.050 |
Why?
|
| Georgia | 1 | 2022 | 87 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2022 | 20 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 517 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 413 | 0.050 |
Why?
|
| Vero Cells | 1 | 2021 | 80 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2022 | 107 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 207 | 0.040 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.040 |
Why?
|
| Candida | 1 | 2020 | 39 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 115 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 127 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 203 | 0.040 |
Why?
|
| Time Factors | 1 | 2007 | 3762 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 483 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2004 | 1989 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 672 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 406 | 0.030 |
Why?
|
| Critical Care | 1 | 2020 | 397 | 0.030 |
Why?
|
| HIV-1 | 1 | 2001 | 721 | 0.030 |
Why?
|
| Mass Screening | 1 | 2021 | 690 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 205 | 0.030 |
Why?
|
| Genes, Viral | 1 | 2015 | 57 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 377 | 0.030 |
Why?
|
| Dependovirus | 1 | 2022 | 709 | 0.030 |
Why?
|
| Male | 3 | 2024 | 29823 | 0.030 |
Why?
|
| Virus Activation | 1 | 2014 | 24 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 319 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2022 | 789 | 0.030 |
Why?
|
| Virus Latency | 1 | 2014 | 32 | 0.030 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2014 | 13 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 263 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 191 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 973 | 0.030 |
Why?
|
| HIV Infections | 1 | 2001 | 967 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2015 | 187 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2015 | 246 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2013 | 36 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 173 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 205 | 0.030 |
Why?
|
| Adolescent | 1 | 2024 | 6241 | 0.020 |
Why?
|
| Survivors | 1 | 2014 | 171 | 0.020 |
Why?
|
| Biological Evolution | 1 | 2013 | 122 | 0.020 |
Why?
|
| Aged | 2 | 2021 | 14393 | 0.020 |
Why?
|
| Genomics | 1 | 2015 | 370 | 0.020 |
Why?
|
| HLA-DR1 Antigen | 1 | 2012 | 27 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2012 | 130 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 131 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 881 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 325 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2012 | 152 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2012 | 175 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 181 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 491 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 300 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 419 | 0.020 |
Why?
|
| Animals | 2 | 2021 | 20619 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2011 | 313 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1617 | 0.020 |
Why?
|
| Cytokines | 1 | 2012 | 934 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1990 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 2607 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2001 | 18 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 2001 | 99 | 0.010 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2001 | 68 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2001 | 178 | 0.010 |
Why?
|
| Virus Replication | 1 | 2001 | 319 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 760 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 10816 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 760 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 2151 | 0.010 |
Why?
|